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Abstract Background: This analysis was performed to further characterise
treatment-emergent hypocalcaemia in patients with bone metastases receiving denosumab.
Methods: Laboratory abnormalities and adverse events of hypocalcaemia in patients with
metastatic bone disease were analysed using data from three identically designed phase 3 trials
of subcutaneous denosumab 120 mg (n = 2841) versus intravenous zoledronic acid 4 mg
(n = 2836).
Results: The overall incidence of laboratory events of hypocalcaemia grade P2 was higher
with denosumab (12.4%) than with zoledronic acid (5.3%). Hypocalcaemia events were pri-
marily grade 2 in severity and usually occurred within the ﬁrst 6 months of treatment.
Patients who reported taking calcium and/or vitamin D supplements had a lower incidence
of hypocalcaemia. Prostate cancer or small-cell lung cancer, reduced creatinine clearance
and higher baseline bone turnover markers of urinary N-telopeptide of type I collagen
(uNTx; >50 versus 650 nmol/mmol) and bone-speciﬁc alkaline phosphatase (BSAP;
>20.77 lg/L [median] versus 620.77 lg/L) values were important risk factors for developing
hypocalcaemia. The risk associated with increased baseline BSAP levels was greater among
patients who had >2 bone metastases at baseline versus those with 62 bone metastases at
baseline.
Conclusion: Hypocalcaemia was more frequent with denosumab versus zoledronic acid, con-
sistent with denosumab’s greater antiresorptive effect. Low serum calcium levels and potential
vitamin D deﬁciency should be corrected before initiating treatment with a potent osteoclast
inhibitor, and corrected serum calcium levels should be monitored during treatment.
Adequate calcium and vitamin D intake appears to substantially reduce the risk of hypocal-
caemia.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
were generally similar; however, hypocalcaemia was
more frequent with denosumab [5]. This retrospective
analysis assessed hypocalcaemia based on laboratory
abnormalities and clinical evaluations collected during
these trials to further identify and characterise potential
risk factors.
2. Patients and methods
2.1. Patients
This retrospective analysis included patient-level data
from three identically designed, double-blind,
double-dummy, international phase 3 trials comparing
the eﬃcacy and safety of denosumab versus ZA for
the prevention of SREs in patients with metastatic bone
disease and advanced breast cancer (NCT00321464)
[12], prostate cancer (NCT00321620) [13], or other solid
tumours or multiple myeloma (NCT00330759) [14].
Details of the study designs and results are published
[5,12–14]. Patients provided written informed consent;
the study protocols were approved by each site’s ethics
committee.
2.2. Study design and treatment
Patients received either subcutaneous denosumab
120 mg (plus intravenous placebo) or intravenous
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Many patients with malignancies develop bone
metastases during disease progression [1–3]. Bone
metastases disrupt the normal homeostasis between
bone formation and resorption by promoting osteoclast
maturation and activity and increased bone resorption
[1]. The shift toward increased bone resorption may
result in bone destruction and skeletal-related events
(SREs), such as pathologic fracture, spinal cord com-
pression, severe pain and the need for skeletal radiation
or surgery [1].
Antiresorptive agents used to treat bone metastases
inhibit osteoclastic bone resorption and reduce skeletal
calcium release into circulation. Hypocalcaemia has
been observed with oral and intravenous bisphospho-
nates and the receptor activator of nuclear
factor-kappa b ligand (RANKL) inhibitor denosumab
[1,4–7]. Risk factors for hypocalcaemia include
osteoblastic metastases [8,9] or extensive osteoid, as in
osteomalacia [10], both of which may act as a calcium
sink. Low baseline serum calcium concentrations [11]
and concurrent corticosteroids [11] have also been asso-
ciated with hypocalcaemia on antiresorptive therapy.
A combined analysis of three phase 3 trials in patients
with metastatic bone disease showed denosumab was
superior to zoledronic acid (ZA) in preventing SREs
[5]. The overall safety proﬁles of denosumab and ZA
infusion of ZA 4 mg (plus subcutaneous placebo) every
4 weeks. ZA dosing was adjusted for renal impairment
per the label and withheld as needed for renal insuﬃ-
ciency. Daily calcium (P500 mg) and vitamin D
(P400 IU equivalent) were strongly recommended for
all patients; supplement intake was collected by patient
report. Study treatment was withheld for any patient
who experienced grade 3 or 4 hypocalcaemia (or any
other adverse event [AE]) reported by the investigator
as treatment related, and resumed when the event
resolved to grade 61.
2.3. Study assessments
Serum calcium (albumin-corrected if albumin was
<4 g/dL), measured every 4 weeks by a central labora-
tory, was analysed to identify hypocalcaemia. The inci-
dence of laboratory hypocalcaemia by grade, deﬁned
by the Common Terminology Criteria for Adverse
Events, version 3.0 [15], was evaluated by treatment
group.
2.4. Hypocalcaemia risk factors
Potential risk factors for hypocalcaemia that were
evaluated were sex and race, calcium and/or vitamin D
supplementation, baseline calculated creatinine clear-
ance, tumour type, bone lesion type, length of exposure
to study drug, baseline levels of bone-speciﬁc alkaline
phosphatase (BSAP) and urinary N-telopeptide of type
I collagen (uNTx), and number of bone metastases at
baseline. Hypocalcaemia incidence was also summarised
by baseline levels of calculated creatinine clearance (ie,
30–<60 mL/min, 60–<90 mL/min and P90 mL/min).
The ﬁrst occurrence of hypocalcaemia was evaluated
by tumour type, time period and timing after dose.
2.5. Statistical analysis
The duration of the ﬁrst occurrence of hypocalcaemia
was calculated from the date of onset of hypocalcaemia
grade P2 to the resolution date (AE) or to a lower
grade of hypocalcaemia (laboratory values). The median
duration of ﬁrst occurrence of hypocalcaemia based
on central laboratory results was estimated using the
Kaplan–Meier method. The impact of on-study
calcium/vitamin D supplement use on the risk of devel-
oping hypocalcaemia for denosumab-treated patients
was evaluated using a time-dependent Cox proportional
hazards model.
A Cox proportional hazards model was used to assess
the baseline covariate signiﬁcance of disease characteris-
tics on the risk of developing grade P2 hypocalcaemia
in univariate and multivariate analyses. Baseline charac-
teristics with P < 0.05 from the univariate analyses were
included in the multivariate model. The interactions of
corrected uNTx and number of bone metastases, and
BSAP and number of bone metastases, were explored
using Cox proportional hazards models with the interac-
tion term and the associated baseline covariates in the
models separately.
3. Results
3.1. Baseline characteristics
Across the three trials, patients were randomised to
denosumab (n = 2862) or ZA (n = 2861; Table 1). In
both treatment groups, baseline characteristics were
generally similar between patients who did and did not
develop on-study hypocalcaemia. Overall, 2841 and
2836 patients in the denosumab and ZA groups, respec-
tively, received P1 dose of study drug and were
included in this analysis.
3.2. Incidence of hypocalcaemia
The incidence of laboratory-detected hypocalcaemia
was higher for denosumab than for ZA overall and for
each grade (Fig. 1A). Similarly, the incidence of
investigator-reported hypocalcaemia AEs was greater
for denosumab than for ZA (Fig. 1B). The majority of
hypocalcaemia events were grade 2; no fatal hypocal-
caemia events occurred during the trials.
Supplementation with calcium and/or vitamin D was
associated with fewer hypocalcaemia AEs for both treat-
ment groups (Fig. 1C and D). With denosumab, the risk
of developing an AE of hypocalcaemia was 40% lower
among patients who reported taking supplements com-
pared with those who did not (hazard ratio [HR], 0.60
[95% conﬁdence interval (CI), 0.45–0.81]; P = 0.0007).
For ZA, the risk of developing hypocalcaemia was
27% lower for those who reported taking supplements
compared with those who did not (HR, 0.73 [95% CI,
0.48–1.11]; P = 0.14).
3.3. First occurrence of hypocalcaemia
Hypocalcaemia occurred earlier for denosumab-
treated than for ZA-treated patients. The median
(Q1, Q3) time to ﬁrst occurrence of hypocalcaemia
grade P2 was 3.8 (1.8, 10.1) months with denosumab
and 6.5 (2.2, 12.0) months with ZA. The median (Q1,
Q3) time to ﬁrst occurrence of hypocalcaemia grade
P3 was longer in both groups: 4.6 (1.8, 12.6) and 7.8
(3.7, 13.8) months, respectively. The corresponding
median (Q1, Q3) times to ﬁrst occurrence of an AE of
hypocalcaemia were 2.8 (1.0, 7.1) and 3.5 (1.0, 9.1)
months.
Of the 353 denosumab-treated patients with hypocal-
caemia grade P2, more than half had prostate cancer
(Table 2). For most denosumab-treated patients and
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Table 1
Demographics and baseline characteristics of randomised patients.
Characteristic, n (%) or median (Q1, Q3) Denosumab (n = 2862) Zoledronic acid (n = 2861)
With hypocalcaemiaa (n = 353) Without hypocalcaemia (n = 2509) With hypocalcaemiaa (n = 149) Without hypocalcaemia (n = 2712)
Sex
Female 116 (32.9) 1200 (47.8) 78 (52.3) 1271 (46.9)
Male 237 (67.1) 1309 (52.2) 71 (47.7) 1441 (53.1)
Age, years 65 (57, 74) 62 (54, 71) 62 (54, 70) 63 (54, 72)
ECOG performance status
0 147 (41.6) 1015 (40.5) 70 (47.0) 1080 (39.8)
1 164 (46.5) 1259 (50.2) 65 (43.6) 1331 (49.1)
2 42 (11.9) 230 (9.2) 14 (9.4) 290 (10.7)
Albumin-adjusted serum calciumb
mg/dL 9.6 (9.3, 10.0) 9.8 (9.5, 10.1) 9.7 (9.4, 9.9) 9.8 (9.5, 10.1)
mmol/L 2.4 (2.3, 2.5) 2.5 (2.4, 2.5) 2.4 (2.4, 2.5) 2.5 (2.4, 2.5)
Serum creatinine, lmol/L 79.6 (61.9, 97.2) 70.7 (61.9, 88.4) 70.7 (61.4, 89.7) 71.6 (61.9, 88.4)
Calculated creatinine clearance >60 mL/minc 278 (78.8) 2068 (82.4) 120 (80.5) 2222 (81.9)
Bone turnover markersd
uNTx, nmol/mmol 59.5 (29.9, 155.4) 41.9 (23.9, 75.2) 49.5 (26.4, 99.4) 42.7 (24.9, 79.5)
BSAP, lg/L 41.4 (18.6, 109.5) 19.8 (13.7, 35.4) 22.0 (14.6, 48.4) 20.5 (13.4, 39.1)
Received study druge 353 (100) 2486 (99.1) 149 (100) 2689 (99.2)
BSAP, bone-speciﬁc alkaline phosphatase; ECOG, Eastern Cooperative Oncology Group; uNTx, urinary N-telopeptide of type I collagen.
a Deﬁned as a laboratory grade P2 event of hypocalcaemia.
b Calcium value was adjusted if albumin level was <4 g/dL.
c The Cockroft–Gault formula was used to estimate creatinine clearance. Values were missing for 19 patients treated with denosumab and 31 patients treated with zoledronic acid.
d Based on patients with baseline values of uNTx or BSAP.
e Two patients randomised to zoledronic acid received denosumab; these two patients are included in the denosumab-treated group for the subsequent analyses.
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across all tumour types, the ﬁrst occurrence of gradeP2
hypocalcaemia or a hypocalcaemia AE was 66 months
after initiating treatment (Table 2); 20.4% of
denosumab-treated patients and 16.1% of ZA-treated
patients experienced grade P2 hypocalcaemia between
the ﬁrst and second doses (Table 3).
Hypocalcaemia generally resolved by the next sched-
uled study visit. Using the beginning and end dates for
the event-of-interest AEs to deﬁne duration, the ﬁrst
occurrence of hypocalcaemia lasted approximately a
median of 3 weeks. Similarly, the Kaplan–Meier esti-
mate of the median duration for ﬁrst occurrence of
hypocalcaemia was 30 days for denosumab and 29 days
for ZA. Of the 502 patients who experienced grade P2
hypocalcaemia, 3 (0.6%) discontinued the study because
of an AE of hypocalcaemia.
Most patients with hypocalcaemia experienced only
one hypocalcaemic episode; 43% of denosumab-treated
patients with hypocalcaemia and 32% of ZA-treated
patients with hypocalcaemia had a recurrent event.
Among denosumab-treated patients, recurrence rates
were highest for those with prostate cancer (94/943,
10%) and lowest for those with non–small-cell lung can-
cer (NSCLC; 3/345, 1%).
3.4. Factors associated with hypocalcaemia
In the denosumab-treated group, more men than
women experienced grade P2 hypocalcaemia (15.4%
versus 8.9%). The ZA-treated group did not show a dif-
ference based on sex (4.7% versus 5.8%). Neither treat-
ment group showed diﬀerences based on race (Table 4).
For each tumour type, the incidence of hypocal-
caemia was higher with denosumab than ZA (Fig. 2).
Among denosumab-treated patients, those with prostate
cancer or small-cell lung cancer (SCLC) had the highest
incidence of hypocalcaemia. For patients receiving ZA,
the incidence of hypocalcaemia was highest in those with
SCLC or multiple myeloma. Those with NSCLC had
the lowest incidence in both groups.
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Fig. 1. Overall incidence of hypocalcaemia, including laboratory grade P2 events (A), adverse events of hypocalcaemia (B), denosumab adverse
events of hypocalcaemia by supplement subgroups (C), and zoledronic acid adverse events of hypocalcaemia by supplement subgroups (D).
Maximum grade experienced by each patient based on the Common Terminology Criteria for Adverse Events, version 3.0. The supplements
subgroup included patients who reported taking oral calcium and/or vitamin D at any time during the study, excluding those who reported
supplement use only after their ﬁrst hypocalcaemia event. The no-supplements subgroup comprised patients who never reported taking oral
calcium and/or vitamin D during the study as well as those who reported supplement use only after their ﬁrst hypocalcaemia event.
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The incidence of laboratory events of hypocalcaemia
was higher in denosumab-treated patients with lower
baseline values of creatinine clearance compared with
those with higher values. In the denosumab-treated
group, 15.5% of patients with baseline creatinine clear-
ance 30 to <60 mL/min had a hypocalcaemia event,
compared with 12.9% of those with values 60 to
<90 mL/min and 11.0% of those with values
P90 mL/min. The corresponding percentages in the
ZA-treated group were 5.8% (30–<60 mL/min), 4.4%
(60–<90 mL/min) and 5.8% (P90 mL/min).
The denosumab-treated patients who developed
hypocalcaemia had higher baseline uNTx and BSAP
levels than those who did not (Table 1). Similarly, the
ZA-treated patients who developed hypocalcaemia also
had higher baseline uNTx levels than those who did
not, although baseline BSAP levels were similar.
Covariate analyses of baseline characteristics showed
several factors associated with risk of developing
gradeP 2 hypocalcaemia in denosumab-treated
patients. In the univariate analysis, male sex, prostate
cancer, SCLC, reduced creatinine clearance (30–
<60 mL/min), higher baseline values of uNTx and
BSAP, >2 bone metastases at baseline, interaction of
baseline values of BSAP and the number of bone metas-
tases, and osteoblastic lesions were signiﬁcantly associ-
ated with an increased risk of developing
hypocalcaemia (Table 4).
In the multivariate analysis, an increased risk of
developing hypocalcaemia was found for patients with
prostate cancer or SCLC, reduced creatinine clearance
(30–<60 mL/min) and higher baseline values of uNTx
and BSAP (Table 4). The risk associated with increased
baseline BSAP levels was greater among patients who
also had >2 bone metastases at baseline versus patients
with 62 bone metastases. Bone lesion type (osteolytic,
osteoblastic, or mixed) at baseline did not increase the
risk for developing hypocalcaemia (all PP 0.2697).
4. Discussion
Hypocalcaemia occurred more frequently in deno-
sumab recipients than in ZA recipients, as measured
by both laboratory values and AEs. The risk of develop-
ing hypocalcaemia AEs was 40% lower in
denosumab-treated patients who reported taking cal-
cium/vitamin D supplements. Univariate analysis identi-
ﬁed several risk factors associated with the development
Table 2
First occurrence of hypocalcaemia by tumour type and time period in patients treated with denosumab.
Tumour type, n (%) Time period
0–6 months >6–12 months >12–24 months >24 months
Laboratory event of grade P2 hypocalcaemia
All tumour types (n = 353) 219 (62.0) 67 (19.0) 59 (16.7) 8 (2.3)
Breast cancer (n = 86) 44 (51.2) 22 (25.6) 19 (22.1) 1 (1.2)
Prostate cancer (n = 193) 115 (59.6) 39 (20.2) 32 (16.6) 7 (3.6)
Multiple myeloma (n = 11) 8 (72.7) 1 (9.1) 2 (18.2) 0 (0)
SCLC (n = 11) 10 (90.9) 0 (0) 1 (9.1) 0 (0)
NSCLC (n = 18) 15 (83.3) 3 (16.7) 0 (0) 0 (0)
Other (n = 34) 27 (79.4) 2 (5.9) 5 (14.7) 0 (0)
Adverse events of hypocalcaemia
All tumour types (n = 313) 193 (61.7) 72 (23.0) 42 (13.4) 6 (1.9)
Breast cancer (n = 65) 36 (55.4) 15 (23.1) 13 (20.0) 1 (1.5)
Prostate cancer (n = 137) 80 (58.4) 35 (25.5) 17 (12.4) 5 (3.6)
Multiple myeloma (n = 15) 9 (60.0) 3 (20.0) 3 (20.0) 0 (0)
SCLC (n = 5) 4 (80.0) 1 (20.0) 0 (0) 0 (0)
NSCLC (n = 36) 28 (77.8) 5 (13.9) 3 (8.3) 0 (0)
Other (n = 55) 36 (65.5) 13 (23.6) 6 (10.9) 0 (0)
NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer.
Table 3
Timing of ﬁrst occurrence of hypocalcaemia by dose.a
Dose timing, n (%) Grade P2 hypocalcaemia Grade P3 hypocalcaemia
Denosumab (n = 353) Zoledronic acid (n = 149) Denosumab (n = 88) Zoledronic acid (n = 38)
Between doses 1 and 2 72 (20.4) 24 (16.1) 19 (21.6) 2 (5.3)
Between doses 2 and 3 55 (15.6) 14 (9.4) 6 (6.8) 3 (7.9)
Between doses 3 and 4 34 (9.6) 8 (5.4) 10 (11.4) 3 (7.9)
Between doses 4 and 5 22 (6.2) 8 (5.4) 6 (6.8) 3 (7.9)
Between doses 5 and 6 23 (6.5) 8 (5.4) 7 (8.0) 2 (5.3)
After dose 6 147 (41.6) 87 (58.4) 40 (45.5) 25 (65.8)
a Includes patients who received one or more doses of study drug and experienced an adverse event of hypocalcaemia.
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Table 4
Baseline factors and risk of developing hypocalcaemia grade P2.
Baseline disease characteristic Univariate analysisa Multivariate analysis
Point estimate 95% CI P value Point estimate 95% CI P value
Sex
Male (n = 1535) 2.083 1.667–2.603 <0.0001 0.761 0.459–1.262 0.2902
Female (n = 1306)
Race
White (n = 2404) 1.080 0.801–1.457 0.6141
Non-white (n = 437)
Tumour type
Breast cancer (n = 1020) 1.024 0.615–1.706 0.9263 0.849 0.441–1.635 0.6249
Prostate cancer (n = 943) 2.966 1.827–4.814 <0.0001 2.193 1.210–3.974 0.0096
Multiple myeloma (n = 86) 1.582 0.746–3.356 0.2319 2.082 0.908–4.771 0.0831
SCLC (n = 61) 4.211 1.989–8.915 0.0002 4.982 2.252–11.021 <0.0001
Other (n = 386) 1.546 0.873–2.738 0.1354 1.484 0.767–2.869 0.2409
NSCLC (n = 345)
Baseline creatinine clearance, mL/min
30–<60 (n = 470) 1.649 1.242–2.189 0.0005 1.414 1.039–1.924 0.0276
60–<90 (n = 1080) 1.207 0.954–1.527 0.1162 1.183 0.919–1.524 0.1918
P90 (n = 1268)
Baseline corrected uNTx level (>50 versus 650 nmol/mmol; n = 1125 versus 1429,
respectively)
1.971 1.581–2.457 <0.0001 1.305 1.018–1.673 0.0360
Baseline BSAP level (>median versus 6median; 20.77 lg/L; n = 1319 versus 1305,
respectively)
2.702 2.134–3.419 <0.0001 1.734 1.280–2.348 0.0004
Bone metastases (>2 versus 62; n = 695 versus 2146, respectively) 1.814 1.459–2.144 <0.0001 0.631 0.312–1.275 0.1995
Interaction between baseline BSAP level (>median versus 6median; 20.77 lg/L) and
number of bone metastases (>2 versus 6 2)
1.981 1.028–3.821 0.0412 2.419 1.154–5.071 0.0193
BSAP level (>median versus 6median; 20.77 lg/L) and >2 bone metastases at baseline – – – 4.193 2.091–8.410 –
BSAP level (>median versus 6median; 20.77 lg/L) and 62 bone metastases at baseline – – – 1.734 1.280–2.348 –
Interaction between baseline corrected uNTx level (>50 versus 6 50 nmol/mmol) and
number of bone metastases (>2 versus 6 2)
1.614 0.973–2.676 0.0638 – – –
Lesion type
Osteolytic (n = 380) 1.040 0.698–1.552 0.8458 0.881 0.554–1.401 0.5922
Osteoblastic (n = 1023) 1.994 1.527–2.605 <0.0001 1.197 0.870–1.647 0.2697
Mixed (n = 537) 1.299 0.928–1.818 0.1268 0.952 0.638–1.421 0.8105
Not seen (n = 901)
BSAP, bone-speciﬁc alkaline phosphatase; CI, conﬁdence interval; NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer; uNTx, urinary N-telopeptide of type I collagen.
a Univariate covariate analysis stratiﬁed by study. Only baseline characteristics with P < 0.05 from the univariate analyses were included in the multivariate model.
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of grade P2 hypocalcaemia, including male sex, pros-
tate cancer or SCLC, reduced creatinine clearance,
higher baseline values of uNTx and BSAP, >2 bone
metastases at baseline, and osteoblastic lesions. In the
multivariate analysis, risk factors associated with
hypocalcaemia included prostate cancer or SCLC,
reduced creatinine clearance and higher baseline values
of uNTx and BSAP.
Denosumab and ZA inhibit bone resorption by dis-
tinct mechanisms, and preclinical and clinical data indi-
cate RANKL inhibitors are more potent at reducing
bone turnover and destruction and the associated
release of skeletal calcium than intravenous bisphospho-
nates [16,17]. Importantly, the identiﬁed risk factors for
hypocalcaemia with denosumab were similar to those
previously ascribed to potent bisphosphonates, such as
vitamin D deﬁciency, renal insuﬃciency and prostate
cancer [18–20]. In our analysis, calcium and/or
vitamin D supplementation at any time during deno-
sumab therapy signiﬁcantly lowered the risk of AEs of
hypocalcaemia.
Previous analyses of hypocalcaemia in cancer
patients treated with denosumab have relied primarily
on clinical AE reports, which only include symptomatic
hypocalcaemia events [21,22]. Results from a
meta-analysis of data from seven randomised controlled
trials demonstrated a higher risk of AEs of hypocal-
caemia among denosumab versus control groups [23].
Our analysis included laboratory events of hypocal-
caemia using patient-level data from three identically
designed trials, including non-symptomatic events.
Osteoclast inhibition rarely results in clinically impor-
tant declines in blood calcium in healthy individuals
[24]. Clinically meaningful hypocalcaemia during antire-
sorptive therapy is typically associated with inadequate
vitamin D intake; insuﬃcient calcium intake; impaired
renal function; hypoparathyroidism; or extensive
osteoid due to high bone turnover, osteomalacia, rapid
skeletal growth, or Paget disease [25–28]. In our analy-
sis, denosumab-treated patients who developed hypocal-
caemia had higher baseline uNTx levels and median
baseline BSAP levels twice as high as those who did
not. Elevated BSAP levels may indicate potential cal-
cium deposition in osteoid and undermineralised bone
matrix, a phenomenon that can persist for weeks or
months after osteoclast inhibition. These results suggest
that patients with high bone turnover may be more
susceptible to hypocalcaemia when osteoclasts are inhib-
ited, particularly when calcium and vitamin D intake
is insuﬃcient. This observation corroborates the
importance of calcium and vitamin D intake in compen-
sating for antiresorptive-mediated reductions in bone
resorption.
Hypocalcaemia incidence with denosumab was lower
in patients with normal baseline creatinine clearance
levels, consistent with the kidney’s role in compensating
for decreased skeletal calcium mobilisation. Osteoclast
inhibition via denosumab typically leads to increased
parathyroid hormone (PTH) release [29], and function-
ally impaired kidneys may be less eﬀective at producing
active vitamin D (1,25(OH)2D3; calcitriol) in response
to this PTH signal. Serum calcitriol was not measured
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in these studies, but impaired renal production of cal-
citriol could diminish intestinal calcium absorption, lead-
ing to increased risk of hypocalcaemia with
antiresorptive therapy. In this analysis, treatment with
ZA in patients with the lowest levels of creatinine clear-
ance had a similar subject incidence of hypocalcaemia
compared with those with normal creatinine clearance.
This could be explained by the downward dose adjust-
ment of ZA in patients with impaired renal function (in
18% of patients) [5], which may have mitigated hypocal-
caemia incidence.
Our ﬁndings suggest a potentially important contri-
bution of osteoid as a risk factor for hypocalcaemia.
Hypocalcaemia was most common in patients with pros-
tate cancer, in whom skeletal metastases often produce
newly formed bone and mineralising osteoid, which
can continue to absorb extracellular calcium after osteo-
clastic activity is inhibited. Recent preclinical data indi-
cate that calcium absorption by osteoid plays an
important role in serum calcium reductions after osteo-
clasts are inhibited by denosumab [30]. Furthermore,
across all tumour types, the risk of hypocalcaemia was
greatest during the ﬁrst 6 months after initiating deno-
sumab. Denosumab maximally decreases bone resorp-
tion markers within 2 weeks, whereas bone formation
markers reach maximal reductions after 3–6 months
[21,31,32]. Thus, although denosumab rapidly decreases
skeletal calcium release, the newly formed underminer-
alised matrix may continue to absorb extracellular cal-
cium for several weeks or months [31]. The rate of
occurrence of hypocalcaemia in the current study was
lower and generally stable beyond 6 months after initiat-
ing denosumab, consistent with the predicted closure
and mineralisation of the remodeling space [33].
It is unlikely that hypocalcaemia in clinical practice
persists for as long as suggested in our analysis [34].
Frequent measurements used in clinical practice to mon-
itor for resolution of hypocalcaemia were not required
or reported in these trials; thus, resolution may have
occurred between study visits but was not detected until
the next study-directed visit.
In summary, hypocalcaemia is a known risk associ-
ated with antiresorptive therapies, including denosumab
120 mg. It is important to correct hypocalcaemia, or any
potential vitamin D deﬁciency, before initiating deno-
sumab or another antiresorptive agent, particularly in
patients exhibiting factors associated with increased risk
(prostate cancer or SCLC, reduced creatinine clearance
and higher baseline values of uNTx and BSAP).
Hypocalcaemia associated with antiresorptive therapies
may be prevented by counseling patients on the impor-
tance of adequate calcium and vitamin D intake, advis-
ing them of the pertinent symptoms of hypocalcaemia,
and monitoring of serum calcium levels, particularly
within the ﬁrst weeks, during therapy. Hypocalcaemia
occurring in this setting should be appropriately
managed, including administration of intravenous cal-
cium if required. With proactive and careful monitoring,
hypocalcaemia is preventable and eﬀectively manage-
able when manifested.
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